Market news

Tango Therapeutics (TNGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tango Therapeutics stock reaction and recent performance Tango Therapeutics (TNGX) has drawn investor attention after recent trading moves, with the stock closing at US$22.76 on the latest trading day. The price change offers a fresh prompt to reassess the company’s recent performance. Over the past month, Tango Therapeutics stock has fallen about 22%, while the past 3 months show a gain of roughly 13%. Year to date, the stock return is about 155%, and the 1-year total return is about...

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (Tango Therapeutics or the Company) today announced that, effective September 1, 2026, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 146,500 shares of its common stock and 40,000 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan. The Tango Therapeutics 2023 Inducement Plan is used exclusively for th

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX) (“Tango Therapeutics” or the “Company”) today announced that members of the management team are scheduled to participate in a fireside chat at the 2026 Cantor Global Healthcare Conference on Wednesday, September 9, 2026 at 8:35 AM EDT. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of the webcast will be a

Vopimetostat+daronxrasib shows an early pancreatic-cancer signal, but data is limited. Click for more on TNGX stock.

Detailed price information for Maze Therapeutics Inc (MAZE-Q) from The Globe and Mail including charting and trades.

Detailed price information for Tango Therapeutics Inc (TNGX-Q) from The Globe and Mail including charting and trades.

Tango Therapeutics stock falls 5% on a wider-than-expected Q2 loss, reflecting higher operating expenses, while pipeline progress remains in focus.

Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination study of vopimetostat + RAS(ON) inhibitors in pancreatic cancer to be presented at 2026 ESMO Congress Key appointments further position Company for late-stage development and commercialization: Robert Azelby, Chairman of the Board of Directors and Fatma Ocak, Chief Commercialization Officer Cash p

Detailed price information for Tango Therapeutics Inc (TNGX-Q) from The Globe and Mail including charting and trades.

Tango Therapeutics (TNGX) executive chairman Barbara Weber has decided to step down from the role, t

BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that Dr. Barbara Weber, the Executive Chairman of the Board of Directors of Tango Therapeutics, will be stepping down in connection with other pursuits. “I am proud with what we have achieved at Tango and am confident that the Company is extremely well positioned to buil

Medical sector earnings are off to a strong start, and four biotech companies are positioned to potentially beat estimates in upcoming quarterly results.

The average of price targets set by Wall Street analysts indicates a potential upside of 49.5% in Tango Therapeutics (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Experienced enterprise software executive to lead company’s next phase of growth Ammon Lesher Tango welcomes Ammon Lesher as its new Chief Executive Officer. DALLAS, July 21, 2026 (GLOBE NEWSWIRE) -- Tango, the leading provider of cloud-based real estate and facilities management software solutions, today announced the appointment of Ammon Lesher as its new Chief Executive Officer. Ammon brings more than a decade of leadership experience building and scaling companies that serve the built enviro

Tango Therapeutics Inc. (NASDAQ:TNGX) is one of the 10 affordable biotech stocks to buy right now. On June 29, Canaccord Genuity increased its target price on Tango Therapeutics Inc. (NASDAQ:TNGX) from $42 to $46, resulting in more than 53% upside potential. The firm kept a Buy rating on the stock, highlighting further upside from vopimetostat + […]